bisoprolol has been researched along with Chronic Illness in 58 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 9.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "Bisoprolol might be superior to carvedilol in providing protection from myocardial injury and preserving pulmonary function in patients with chronic systolic heart failure." | 9.24 | Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. ( Abe, S; Amano, H; Arikawa, T; Haruyama, A; Inami, S; Inoue, T; Node, K; Sakuma, M; Tanaka, A; Toyoda, S, 2017) |
| "We investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure." | 9.22 | Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ( Anker, SD; Cvan Trobec, K; Grabnar, I; Kerec Kos, M; Lainscak, M; Rosano, G; Trontelj, J; Vovk, T, 2016) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 9.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure." | 9.17 | Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. ( Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G, 2013) |
| "The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF)." | 9.17 | Population pharmacokinetics of bisoprolol in patients with chronic heart failure. ( Apostolović, S; Deljanin-Ilic, M; Ilic, S; Jankovic, SM; Jevtovic-Stoimenov, T; Marinkovic, D; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zecevic, DR; Zivanovic, S, 2013) |
| "Carvedilol and bisoprolol reduce QT dispersion (QTD) in chronic heart failure (CHF)." | 9.14 | The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. ( Aygul, MU; Aygul, N; Duzenli, MA; Ozdemir, K, 2009) |
| "To assess the clinical effects and safety profile of initial monotherapy with either bisoprolol or enalapril in elderly patients with heart failure (HF)." | 9.13 | Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. ( Dobre, D; Goulder, MA; Krum, H; van Veldhuisen, DJ; Willenheimer, R, 2008) |
| "Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia." | 9.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF)." | 9.12 | Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? ( Agostoni, P; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Fiorentini, C; Palermo, P; Sciomer, S, 2007) |
| "Economic analysis of bisoprolol plus standard therapy versus placebo plus standard therapy in the treatment of chronic heart failure in Germany." | 9.09 | [Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. ( Follath, F; Paschen, B; Schwenkglenks, M; Szucs, TD, 2000) |
| "The efficacy and safety of the new cardioselective beta-blocker bisoprolol 5 mg and 10 mg once daily in the treatment of angina pectoris was compared with atenolol 100 mg once daily." | 9.06 | A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris. ( Camm, AJ; Dymond, DS; Maltz, MB; Nathan, AW, 1987) |
| " For search on PubMed, the following search terms will be used: "trimetazidine, bisoprolol, chronic heart failure, chronic obstructive pulmonary disease." | 8.02 | Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. ( Fu, B; Ma, S; Zhang, X, 2021) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "To identify the prevalence and characteristics of recently hospitalized chronic heart failure (CHF) patients in community care who meet the indication for ivabradine." | 7.81 | Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. ( Charles, H; Cochrane, L; Elder, DH; Lang, CC; Mohan, M, 2015) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 7.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "The purpose of the study was to assess the efficacy and tolerance of the beta1-selective beta-adrenoceptor-blocking agent bisoprolol in patients with chronic stable angina pectoris." | 7.68 | Bisoprolol in the treatment of chronic stable angina pectoris. ( Plaza, L; Rodrigo, F; Terol, I, 1990) |
| "The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis." | 7.67 | Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. ( Dorow, P; Tönnesmann, U, 1984) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 6.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists." | 6.49 | [Epidemiology and treatment of chronic heart failure; use of bisoprolol]. ( Nagy, V, 2013) |
| "Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients." | 6.44 | Bisoprolol in the treatment of chronic heart failure. ( de Groote, P; Ennezat, PV; Mouquet, F, 2007) |
| "We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure." | 6.20 | Beta-blocker benefit according to severity of heart failure. ( Bouzamondo, A; Hulot, JS; Lechat, P; Sanchez, P, 2003) |
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 5.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "Bisoprolol might be superior to carvedilol in providing protection from myocardial injury and preserving pulmonary function in patients with chronic systolic heart failure." | 5.24 | Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. ( Abe, S; Amano, H; Arikawa, T; Haruyama, A; Inami, S; Inoue, T; Node, K; Sakuma, M; Tanaka, A; Toyoda, S, 2017) |
| "We investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure." | 5.22 | Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ( Anker, SD; Cvan Trobec, K; Grabnar, I; Kerec Kos, M; Lainscak, M; Rosano, G; Trontelj, J; Vovk, T, 2016) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 5.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF)." | 5.17 | Population pharmacokinetics of bisoprolol in patients with chronic heart failure. ( Apostolović, S; Deljanin-Ilic, M; Ilic, S; Jankovic, SM; Jevtovic-Stoimenov, T; Marinkovic, D; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zecevic, DR; Zivanovic, S, 2013) |
| "Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure." | 5.17 | Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. ( Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G, 2013) |
| "to evaluate of the effectiveness of switching from beta-adrenoblockers (BAB) non-included into the guidelines for the management of chronic heart failure (CHF) to nebivolol and bisoprolol for outpatients." | 5.14 | [Optimization of use of beta-adrenoblockers in the treatment of chronic heart failure in the outpatient setting]. ( Ageev, FT; Blankova, ZN; Kheĭmets, GI; Kuz'mina, AE; Ovchinnikov, AG; Patrusheva, IF; Seredenina, EM; Zhubrina, ES, 2009) |
| "Carvedilol and bisoprolol reduce QT dispersion (QTD) in chronic heart failure (CHF)." | 5.14 | The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. ( Aygul, MU; Aygul, N; Duzenli, MA; Ozdemir, K, 2009) |
| "to study the safety of switching from short-acting metoprolol to long-acting bisoprolol in patients with cardiac failure and postinfarction impaired left ventricular systolic function." | 5.13 | Switching beta-blocker therapy in chronic heart failure. ( Somlói, M; Toldy-Schedel, E; Tomcsányi, J; Wettstein, A, 2008) |
| "Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia." | 5.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "To assess the clinical effects and safety profile of initial monotherapy with either bisoprolol or enalapril in elderly patients with heart failure (HF)." | 5.13 | Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. ( Dobre, D; Goulder, MA; Krum, H; van Veldhuisen, DJ; Willenheimer, R, 2008) |
| "To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF)." | 5.12 | Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? ( Agostoni, P; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Fiorentini, C; Palermo, P; Sciomer, S, 2007) |
| "The study was undertaken to evaluate the effects of long-term (6-month) therapy with the selective beta-blocker bisoprolol, the cytoprotector trimetazidine and their combination on the clinical course of disease, the morphofunctional parameters of the left ventricle (LV) and life quality in 71 patients with coronary heart disease (CHD) concurrent with functional classes (FC) III-IV chronic heart failure (CHF) (ejection fraction (EF) < 35%, as evidenced by echoCG)." | 5.11 | [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease]. ( Fedorova, TA; Il'ina, IuV; Rybakova, MK; Sotnikova, TI, 2004) |
| "Economic analysis of bisoprolol plus standard therapy versus placebo plus standard therapy in the treatment of chronic heart failure in Germany." | 5.09 | [Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. ( Follath, F; Paschen, B; Schwenkglenks, M; Szucs, TD, 2000) |
| "The efficacy and safety of the new cardioselective beta-blocker bisoprolol 5 mg and 10 mg once daily in the treatment of angina pectoris was compared with atenolol 100 mg once daily." | 5.06 | A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris. ( Camm, AJ; Dymond, DS; Maltz, MB; Nathan, AW, 1987) |
| " For search on PubMed, the following search terms will be used: "trimetazidine, bisoprolol, chronic heart failure, chronic obstructive pulmonary disease." | 4.02 | Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. ( Fu, B; Ma, S; Zhang, X, 2021) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Clinical efficacy and adverse effects of the β-blocking agents, carvedilol, bisoprolol, and metoprolol were analyzed theoretically, and then compared quantitatively, for the purpose of determining their proper use for chronic heart failure." | 3.85 | Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure. ( Fujito, K; Kimura, K; Takayanagi, R; Yamada, Y, 2017) |
| "To identify the prevalence and characteristics of recently hospitalized chronic heart failure (CHF) patients in community care who meet the indication for ivabradine." | 3.81 | Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. ( Charles, H; Cochrane, L; Elder, DH; Lang, CC; Mohan, M, 2015) |
| "25 mg of hydrochlorothiazide, the clinical condition, the daily profile of blood pressure, body adrenoreactivity structural and functional parameters of the left ventricle in 28 pregnant women with preeclampsia in the background chronic hypertension (hypertension stage II, 2 nd degree) and 28 pregnant women with preeclampsia and mild to moderate severity in terms of 22-28 weeks of pregnancy." | 3.78 | [Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia]. ( Manukhin, IB; Markova, EV; Markova, LI; Striuk, RI, 2012) |
| " We investigated pulmonary protein and amino acid metabolism, the biochemical basis of the remodeling process, in individuals with chronic heart failure receiving or not receiving β-blocker therapy with bisoprolol (BIS)." | 3.78 | Lung anabolic activity in patients with chronic heart failure: potential implications for clinical practice. ( Aquilani, R; Baiardi, P; Bongiorno, AI; Boschi, F; Dossena, M; Febo, O; Iadarola, P; La Rovere, MT; Pastoris, O; Verri, M; Viglio, S, 2012) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 3.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "The purpose of the study was to assess the efficacy and tolerance of the beta1-selective beta-adrenoceptor-blocking agent bisoprolol in patients with chronic stable angina pectoris." | 3.68 | Bisoprolol in the treatment of chronic stable angina pectoris. ( Plaza, L; Rodrigo, F; Terol, I, 1990) |
| "The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis." | 3.67 | Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. ( Dorow, P; Tönnesmann, U, 1984) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 2.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| " The dosage of beta-blockers were increased gradually to target or the tolerant dosages (bisoprolol 10 mg qd, carvedilol 25 mg bid) during 3 months in 36 patients." | 2.71 | [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]. ( Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM, 2005) |
| "The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists." | 2.49 | [Epidemiology and treatment of chronic heart failure; use of bisoprolol]. ( Nagy, V, 2013) |
| "Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients." | 2.44 | Bisoprolol in the treatment of chronic heart failure. ( de Groote, P; Ennezat, PV; Mouquet, F, 2007) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| " The primary outcome was the change in equivalent dosing of ramipril and bisoprolol at 6-months." | 1.62 | Impact of the COVID-19 pandemic on the management of chronic heart failure. ( Gierula, J; Jagger, J; McGinlay, M; Nouri, B; Straw, S; Witte, KK, 2021) |
| "Skeletal muscle atrophy and decreased expression of slow fibers contribute to exercise capacity limitation in Chronic Heart Failure (CHF)." | 1.36 | Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree? ( Angelini, A; Betto, DD; Dalla Libera, L; Evangelista, S; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2010) |
| " All centres were provided with carvedilol, metoprolol, and bisoprolol at appropriate doses; the choice of the drug and dosage was left to the responsible clinician." | 1.32 | Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. ( Balli, E; Geraci, E; Gorini, M; Gronda, E; Lucci, D; Maggioni, AP; Opasich, C; Sinagra, G; Tavazzi, L; Tognoni, G, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.17) | 18.7374 |
| 1990's | 3 (5.17) | 18.2507 |
| 2000's | 26 (44.83) | 29.6817 |
| 2010's | 22 (37.93) | 24.3611 |
| 2020's | 4 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Toyoda, S | 2 |
| Haruyama, A | 2 |
| Inami, S | 2 |
| Arikawa, T | 2 |
| Saito, F | 1 |
| Watanabe, R | 1 |
| Sakuma, M | 2 |
| Abe, S | 2 |
| Nakajima, T | 1 |
| Tanaka, A | 2 |
| Node, K | 2 |
| Inoue, T | 2 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 1 |
| Smirnov, A | 1 |
| Zhang, X | 1 |
| Ma, S | 1 |
| Fu, B | 1 |
| McGinlay, M | 1 |
| Straw, S | 1 |
| Jagger, J | 1 |
| Nouri, B | 1 |
| Gierula, J | 1 |
| Witte, KK | 1 |
| Fröhlich, H | 1 |
| Torres, L | 1 |
| Täger, T | 1 |
| Schellberg, D | 1 |
| Corletto, A | 1 |
| Kazmi, S | 1 |
| Goode, K | 1 |
| Grundtvig, M | 1 |
| Hole, T | 1 |
| Katus, HA | 1 |
| Cleland, JGF | 1 |
| Atar, D | 1 |
| Clark, AL | 1 |
| Agewall, S | 1 |
| Frankenstein, L | 1 |
| Takayanagi, R | 1 |
| Fujito, K | 1 |
| Kimura, K | 1 |
| Yamada, Y | 1 |
| Momomura, SI | 1 |
| Saito, Y | 1 |
| Yasumura, Y | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 1 |
| Daimon, M | 1 |
| Kinugawa, K | 1 |
| Okamoto, H | 1 |
| Dohi, N | 1 |
| Komuro, I | 1 |
| Hori, M | 1 |
| Nagai, R | 1 |
| Izumi, T | 1 |
| Matsuzaki, M | 1 |
| Yamashita, T | 1 |
| Inoue, H | 1 |
| Nagy, V | 1 |
| Riccioni, G | 1 |
| Masciocco, L | 1 |
| Benvenuto, A | 1 |
| Saracino, P | 1 |
| De Viti, D | 1 |
| Massari, F | 1 |
| Meliota, G | 1 |
| Buta, F | 1 |
| Speziale, G | 1 |
| Düngen, HD | 1 |
| Musial-Bright, L | 1 |
| Inkrot, S | 1 |
| Apostolović, S | 2 |
| Edelmann, F | 1 |
| Lainščak, M | 4 |
| Sekularac, N | 1 |
| Störk, S | 1 |
| Tahirovic, E | 1 |
| Tscholl, V | 1 |
| Krackhardt, F | 1 |
| Loncar, G | 1 |
| Trippel, TD | 1 |
| Gelbrich, G | 1 |
| Javed, O | 1 |
| Koo, K | 1 |
| El-Omar, O | 1 |
| Allen, S | 1 |
| Squires, A | 1 |
| El-Omar, M | 1 |
| Elder, DH | 1 |
| Mohan, M | 1 |
| Cochrane, L | 1 |
| Charles, H | 1 |
| Lang, CC | 1 |
| Cvan Trobec, K | 1 |
| Grabnar, I | 1 |
| Kerec Kos, M | 1 |
| Vovk, T | 1 |
| Trontelj, J | 1 |
| Anker, SD | 1 |
| Rosano, G | 1 |
| Miró, Ò | 1 |
| Müller, C | 1 |
| Martín-Sánchez, FJ | 1 |
| Bueno, H | 1 |
| Mebazaa, A | 1 |
| Herrero, P | 1 |
| Jacob, J | 1 |
| Gil, V | 1 |
| Escoda, R | 1 |
| Llorens, P | 1 |
| Amano, H | 1 |
| Dobre, D | 1 |
| van Veldhuisen, DJ | 3 |
| Goulder, MA | 1 |
| Krum, H | 5 |
| Willenheimer, R | 3 |
| Aygul, N | 1 |
| Ozdemir, K | 1 |
| Duzenli, MA | 1 |
| Aygul, MU | 1 |
| Remme, WJ | 1 |
| Dalla Libera, L | 1 |
| Ravara, B | 1 |
| Gobbo, V | 1 |
| Betto, DD | 1 |
| Germinario, E | 1 |
| Angelini, A | 1 |
| Evangelista, S | 1 |
| Vescovo, G | 1 |
| Shaw, SM | 1 |
| Coppinger, T | 1 |
| Waywell, C | 1 |
| Dunne, L | 1 |
| Archer, LD | 1 |
| Critchley, WR | 1 |
| Yonan, N | 1 |
| Fildes, JE | 1 |
| Williams, SG | 1 |
| Zhubrina, ES | 1 |
| Ovchinnikov, AG | 1 |
| Seredenina, EM | 1 |
| Patrusheva, IF | 1 |
| Blankova, ZN | 1 |
| Kuz'mina, AE | 1 |
| Kheĭmets, GI | 1 |
| Ageev, FT | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 1 |
| Keogh, AM | 1 |
| Kotlyar, E | 1 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Hayward, CS | 1 |
| Funck-Brentano, C | 1 |
| Vanoli, E | 1 |
| Silke, B | 2 |
| Erdmann, E | 3 |
| Follath, F | 3 |
| Ponikowski, P | 2 |
| Goulder, M | 1 |
| Meyer, W | 2 |
| Lechat, P | 6 |
| Magrì, D | 1 |
| Palermo, P | 2 |
| Cauti, FM | 1 |
| Contini, M | 2 |
| Farina, S | 1 |
| Cattadori, G | 2 |
| Apostolo, A | 2 |
| Salvioni, E | 1 |
| Magini, A | 1 |
| Vignati, C | 1 |
| Alimento, M | 1 |
| Sciomer, S | 2 |
| Bussotti, M | 2 |
| Agostoni, P | 2 |
| Shilov, AM | 1 |
| Dulaeva, MS | 1 |
| Podbregar, M | 3 |
| Kovacic, D | 2 |
| Rozman, J | 1 |
| von Haehling, S | 1 |
| Manukhin, IB | 1 |
| Markova, EV | 1 |
| Markova, LI | 1 |
| Striuk, RI | 1 |
| Aquilani, R | 1 |
| La Rovere, MT | 1 |
| Febo, O | 1 |
| Baiardi, P | 1 |
| Boschi, F | 1 |
| Iadarola, P | 1 |
| Viglio, S | 1 |
| Dossena, M | 1 |
| Bongiorno, AI | 1 |
| Pastoris, O | 1 |
| Verri, M | 1 |
| Nikolic, VN | 1 |
| Jevtovic-Stoimenov, T | 1 |
| Velickovic-Radovanović, R | 1 |
| Ilic, S | 1 |
| Deljanin-Ilic, M | 1 |
| Marinkovic, D | 1 |
| Stanojevic, D | 1 |
| Zivanovic, S | 1 |
| Stefanovic, N | 1 |
| Pesic, S | 1 |
| Zecevic, DR | 1 |
| Milovanovic, JR | 1 |
| Jankovic, SM | 1 |
| Voga, G | 1 |
| Maggioni, AP | 1 |
| Sinagra, G | 1 |
| Opasich, C | 1 |
| Geraci, E | 1 |
| Gorini, M | 1 |
| Gronda, E | 1 |
| Lucci, D | 1 |
| Tognoni, G | 1 |
| Balli, E | 1 |
| Tavazzi, L | 1 |
| Bouzamondo, A | 1 |
| Hulot, JS | 2 |
| Sanchez, P | 1 |
| Van De Ven, L | 1 |
| Verkenne, P | 3 |
| Fedorova, TA | 1 |
| Il'ina, IuV | 1 |
| Sotnikova, TI | 1 |
| Rybakova, MK | 1 |
| Murakami, T | 1 |
| Wang, F | 1 |
| Xu, ZM | 1 |
| Wang, L | 1 |
| Bian, WY | 1 |
| Jia, X | 1 |
| Duan, B | 1 |
| Li, W | 1 |
| Li, YS | 1 |
| Bailey, M | 1 |
| Dargie, H | 2 |
| Anker, S | 1 |
| Fiorentini, C | 1 |
| Marinsek, M | 1 |
| Gobec, L | 1 |
| Tomcsányi, J | 1 |
| Wettstein, A | 1 |
| Toldy-Schedel, E | 1 |
| Somlói, M | 1 |
| de Groote, P | 2 |
| Delour, P | 1 |
| Mouquet, F | 2 |
| Lamblin, N | 1 |
| Dagorn, J | 1 |
| Hennebert, O | 1 |
| Le Tourneau, T | 1 |
| Foucher-Hossein, C | 1 |
| Verkindère, C | 1 |
| Bauters, C | 1 |
| Hamaad, A | 1 |
| Lip, GY | 1 |
| Nicholls, D | 1 |
| MacFadyen, RJ | 1 |
| Ennezat, PV | 1 |
| Dorow, P | 1 |
| Tönnesmann, U | 1 |
| Andréjak, M | 1 |
| Slama, M | 1 |
| vom Dahl, J | 1 |
| Schotten, U | 1 |
| Sasse, A | 1 |
| Bristow, MR | 1 |
| Ertle, G | 1 |
| Hart, SM | 1 |
| Szucs, TD | 1 |
| Schwenkglenks, M | 1 |
| Paschen, B | 1 |
| Escolano, S | 1 |
| Mallet, A | 1 |
| Leizorovicz, A | 1 |
| Werhlen-Grandjean, M | 1 |
| Pochmalicki, G | 1 |
| Wiemann, H | 1 |
| Terol, I | 1 |
| Plaza, L | 1 |
| Rodrigo, F | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Kohli, RS | 1 |
| Lahiri, A | 1 |
| Raftery, EB | 1 |
| Maltz, MB | 1 |
| Dymond, DS | 1 |
| Nathan, AW | 1 |
| Camm, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)[NCT03437369] | Phase 4 | 22 participants (Anticipated) | Interventional | 2018-05-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for bisoprolol and Chronic Illness
| Article | Year |
|---|---|
[Epidemiology and treatment of chronic heart failure; use of bisoprolol].
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chroni | 2013 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
[Beta blockers for therapy of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as | 2005 |
Bisoprolol in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis | 2007 |
[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Bisoprolol; Carbazoles | 1999 |
beta-adrenergic receptor blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hea | 2000 |
Influence of beta-blockers on mortality in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2000 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
30 trials available for bisoprolol and Chronic Illness
| Article | Year |
|---|---|
Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Inflammatory Agents; Bisoprolol; C-Reactive Protein; | 2020 |
Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Asian People; Bisoprolol; Chronic Disease; Fema | 2017 |
Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Disease-Free | 2014 |
Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Atrial Fibrillation; Bisoprolol; Blood Pressure | 2013 |
Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; | 2013 |
Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chronic Di | 2014 |
Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Body Composition; Chron | 2016 |
Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Cardiotonic Agents; Chronic Disease; Femal | 2017 |
Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Bradycardia; Chronic Disease; Cough; Drug | 2008 |
The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Electrocardi | 2009 |
[Optimization of use of beta-adrenoblockers in the treatment of chronic heart failure in the outpatient setting].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Benzopyrans; Bisoprolol; Chronic Disease; Ethano | 2009 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis | 2011 |
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2011 |
Population pharmacokinetics of bisoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Chronic Disease; | 2013 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Blood Press | 2004 |
[Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Topics: Aged; Aged, 80 and over; Bisoprolol; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; M | 2004 |
[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Car | 2005 |
Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Bisoprolol; Cause of Death; Chi-Square Distributi | 2007 |
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Cross-Over S | 2007 |
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Body Weight; Carbazoles; Carvedilol; C | 2008 |
Switching beta-blocker therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Chronic Disease; Heart Failure; Humans; Metoprolol | 2008 |
The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Fail | 2007 |
Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Chroni | 2007 |
[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study].
Topics: Aged; Bisoprolol; Chronic Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Germany; Hear | 2000 |
Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; Chronic Dis | 2001 |
Management of chronic stable angina with once-daily bisoprolol or atenolol and long-term efficacy of bisoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Bisoprolol; Chronic Disease; Do | 1986 |
A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris.
Topics: Aged; Angina Pectoris; Atenolol; Bisoprolol; Chronic Disease; Clinical Trials as Topic; Drug Adminis | 1987 |
21 other studies available for bisoprolol and Chronic Illness
| Article | Year |
|---|---|
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Chronic Disease; Drug Therapy, Combination; Hear | 2021 |
Impact of the COVID-19 pandemic on the management of chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; | 2021 |
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2017 |
Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Forced Expiratory | 2017 |
Clinic and ambulatory heart rates in patients with ischaemic heart disease and/or chronic heart failure taking rate-limiting medications: are they interchangeable?
Topics: Adrenergic beta-1 Receptor Antagonists; Ambulatory Care Facilities; Bisoprolol; Chronic Disease; Ele | 2015 |
Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Bisoprolol; Cardiovascular Agents; Chronic Dis | 2015 |
BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2016 |
Beta-blockade as first-line therapy in the elderly heart failure patient--the proper approach or asking for trouble?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2008 |
Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree?
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Benzopyrans; Bisoprolol; Chronic Disease; Ethanolam | 2010 |
The effect of beta-blockers on the adaptive immune system in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; | 2009 |
Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker dose.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Dose-Respons | 2012 |
[Chronic heart failure--speciale of treatment].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Chronic Disease; Drug Therapy, Combination | 2011 |
[Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia].
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Chronic Disease; Dose-Response Relations | 2012 |
Lung anabolic activity in patients with chronic heart failure: potential implications for clinical practice.
Topics: Adrenergic beta-1 Receptor Antagonists; Airway Remodeling; Amino Acids; Arteries; Bisoprolol; Chroni | 2012 |
Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic | 2003 |
Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Airway Resistance; Bisoprolol; Blood Pressure; Bronchitis; | 1984 |
[Drugs prescribed for chronic heart failure. Current data on their effectiveness].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biso | 1998 |
[CIBIS-II Study. Bisoprolol in patients with chronic heart failure].
Topics: Bisoprolol; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2000 |
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Bisoprolol; Cause of Death; | 2001 |
Bisoprolol in the treatment of chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Bisoprolol; Chi-Square Distribution; Chro | 1990 |